最新一期业绩显示，2025年一季报，公司实现营业收入3.30亿元，同比2.35%；净利润2863.67万元，同 比-32.97%，销售毛利率76.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13福瑞股份116.75102.246.50115.82亿行业平均 53.6550.024.68114.74亿行业中值37.2237.112.6755.30亿1九安医疗11.0111.130.87185.78亿2英科医疗 15.4516.651.37244.06亿3新华医疗15.7214.571.28100.77亿4山东药玻16.0216.071.84151.57亿5振德医疗 16.2915.351.0459.13亿6奥美医疗16.4116.081.6959.27亿7九强生物17.4416.212.1486.36亿8康德莱 17.6117.631.4637.96亿9维力医疗17.6918.902.2341.47亿10奥泰生物18.1519.141.4757.89亿11鱼跃医疗 19.8419.462.68351.37亿12安图生物20.0619.152.58228.74亿 来源：金融界 从行业市盈率排名 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Furuya Co., which has a closing price of 44.82 yuan, a PE ratio of 119.72, and a total market value of 11.876 billion yuan [1][2] - Furuya Co. ranks 107th in the medical device industry based on PE ratio, with the industry average at 54.89 and the median at 37.06 [1][2] - The company experienced a net inflow of 15.51 million yuan in principal funds on July 31, with a total inflow of 27.94 million yuan over the past five days [1] Group 2 - Furuya Co. specializes in the production and sales of drugs in the liver disease field, development and sales of diagnostic equipment, and related medical services, with its main product being the compound turtle shell soft liver tablets [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 330 million yuan, a year-on-year increase of 2.35%, while net profit was 28.64 million yuan, a year-on-year decrease of 32.97%, with a gross profit margin of 76.76% [1]

内蒙古福瑞医疗科技股份有限公司的主营业务是肝病领域的药品生产与销售、诊断设备研发与销售以及 医疗服务相关业务。公司的主要产品是复方鳖甲软肝片。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.15倍，行业中值37.48倍，福瑞股份排 名第107位。 股东方面，截至2025年7月10日，福瑞股份股东户数20833户，较上次减少220户，户均持股市值35.28万 元，户均持股数量2.76万股。 7月30日，福瑞股份今日收盘43.54元，下跌1.54%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到116.30倍，总市值115.37亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入3.30亿元，同比2.35%；净利润2863.67万元，同 比-32.97%，销售毛利率76.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13福瑞股份116.30101.846.47115.37亿行业平均 55.1550.114.80115.74亿行业中值37.4836.822.6955.61亿1九安医疗11.0711.200.87186.87亿2英科医疗 14.0715.171.2 ...

金融界消息 截至2025年7月29日收盘，福瑞股份（300049）报收于44.22元，下跌1.18%，换手率 3.29%，成交量7.68万手，成交金额3.39亿元。 资金流向方面，今日主力资金净流出2119.99万元，占比成交额6.26%。其中，超大单净流出1771.16万 元、占成交额5.23%，大单净流出348.84万元、占成交额1.03%，中单净流出流入2577.71万元、占成交 额7.61%，小单净流出457.72万元、占成交额1.35%。 福瑞股份最新一期业绩显示，截至2025一季报，公司营业总收入3.30亿元、同比增长2.35%，归属净利 润2863.67万元，同比减少32.97%，扣非净利润2970.71万元，同比减少28.05%，流动比率4.564、速动比 率4.141、资产负债率28.99%。 天眼查商业履历信息显示，内蒙古福瑞医疗科技股份有限公司，成立于2001年，位于乌兰察布市，是一 家以从事医药制造业为主的企业。企业注册资本26497.59万人民币，实缴资本13931.5035万人民币。公 司法定代表人为王冠一。 通过天眼查大数据分析，内蒙古福瑞医疗科技股份有限公司共对外投资了23家企 ...

最新一期业绩显示，2025年一季报，公司实现营业收入3.30亿元，同比2.35%；净利润2863.67万元，同 比-32.97%，销售毛利率76.76%。 7月29日，福瑞股份今日收盘44.22元，下跌1.18%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到118.11倍，总市值117.17亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.46倍，行业中值37.74倍，福瑞股份排 名第107位。 截至2025年一季报，共有13家机构持仓福瑞股份，其中基金13家，合计持股数656.28万股，持股市值 2.13亿元。 内蒙古福瑞医疗科技股份有限公司的主营业务是肝病领域的药品生产与销售、诊断设备研发与销售以及 医疗服务相关业务。公司的主要产品是复方鳖甲软肝片。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13福瑞股份118.11103.436.58117.17亿行业平均 55.4650.344.76115.47亿行业中值37.7437.642.7056.85亿1九安医疗10.9411.070.86184.69亿2英科医疗 13.3414.381.19210.74亿3新华医 ...

Core Viewpoint - The company has completed the repurchase and cancellation of certain restricted stocks as part of its 2024 stock incentive plan, following the departure of some incentive targets and failure to meet performance targets for the first release period. Group 1: Stock Repurchase and Cancellation - The company repurchased and canceled 138,020 shares of restricted stock at a price of 18.09 yuan per share, totaling approximately 24,967,818 yuan, funded by its own resources [1][6][5] - The repurchase was necessitated by the departure of 8 incentive targets and the failure to meet the performance criteria for the first release period, which required a net profit of at least 20 million yuan for 2024 [3][8] Group 2: Approval Process - The company held multiple board and supervisory meetings to approve the stock incentive plan and its amendments, with the latest approvals occurring on April 25, 2024, and May 21, 2024 [2][3] - The supervisory board confirmed the list of incentive targets and the public notice period did not receive any objections [2][3] Group 3: Impact on Company Structure - Following the repurchase, the company's total registered capital decreased to 264,975,900 yuan, with the total number of shares reduced to 264,975,900 [6][7] - The shareholding structure remains compliant with listing requirements, and the controlling shareholder's status has not changed [7][6] Group 4: Future Performance Conditions - The performance conditions for the release of restricted stocks are set for the years 2024 to 2026, with required net profits of 20 million yuan, 30 million yuan, and 40 million yuan respectively for each year [8]

证券代码：300049 证券简称：福瑞股份 公告编号：2025-029 内蒙古福瑞医疗科技股份有限公司关于 2024 年限制性股票激励计划部分限制性股票回购注销完成的公告 （一）2024年1月31日，公司召开第八届董事会第六次会议，审议通过了《关 于<2024年限制性股票激励计划（草案）>及其摘要的议案》《关于<2024年限制性 股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事会办理公 司2024年限制性股票激励计划有关事宜的议案》，同日，公司召开第八届监事会 第六次会议，审议并通过《关于<2024年限制性股票激励计划（草案）>及其摘要 的议案》《关于<2024年限制性股票激励计划实施考核管理办法>的议案》《关于 核实<2024年限制性股票激励计划激励对象名单>的议案》。 （二）2024年4月25日，公司召开第八届董事会第七次会议，审议通过了《关 于<2024年限制性股票激励计划（草案修订稿）>及其摘要的议案》《关于<2024年 限制性股票激励计划实施考核管理办法（修订稿）>的议案》，同日，公司召开第 八届监事会第七次会议，审议并通过《关于<2024年限制性股票激励计划（草案修 订稿）>及其摘 ...

Core Insights - The report maintains a positive outlook on small molecule drug conjugates (SMDCs) and related companies, highlighting their potential in cancer treatment due to their ability to enhance efficacy while reducing toxicity [1][5][17] - The report emphasizes the clinical advantages of SMDCs, including better tumor penetration, reduced toxicity to normal cells, and easier control over synthesis and costs compared to antibody-drug conjugates (ADCs) [5][11][12] - The report identifies domestic biopharmaceutical companies, particularly Affinivax, as leaders in the SMDC space, showcasing significant advancements in innovative cancer drug development [5][12][17] Industry Overview - The pharmaceutical and biotechnology sector has shown a relative price-to-earnings (P/E) ratio of 51.14 as of July 25, 2025, which is significantly higher than its historical low of 24.38, indicating a premium valuation compared to the broader market [19] - The report notes that the healthcare sector's valuation is 279% higher than the Shanghai Composite Index, reflecting strong investor interest and confidence in the industry [19] - Recent market performance indicates a 1.90% increase in the pharmaceutical and biotechnology sector from July 21 to July 25, 2025, ranking it 16th among 27 sub-industries [26][29] Company Focus - The report suggests monitoring companies involved in the SMDC space, including Affinivax, and those collaborating with them, such as Innovent Biologics and others, which are expected to benefit from the growing interest in innovative cancer therapies [5][17][18] - Specific companies highlighted for their innovative drug development capabilities include Innovent Biologics, Shunyi Pharmaceutical, and others, which are positioned to capitalize on the advancements in SMDC technology [5][18]

Company Overview - Furuya Co., Ltd. closed at 43.16 yuan, up 2.84%, with a rolling PE ratio of 115.88, marking a new low in 182 days, and a total market value of 11.496 billion yuan [1] - The company operates primarily in the liver disease sector, focusing on drug production and sales, diagnostic equipment R&D and sales, and related medical services [1] Financial Performance - For Q1 2025, the company reported revenue of 330 million yuan, a year-on-year increase of 2.35%, while net profit was 28.637 million yuan, reflecting a year-on-year decrease of 32.97%, with a gross margin of 76.76% [1] Shareholder Information - As of July 10, 2025, the number of shareholders for Furuya Co., Ltd. was 20,833, a decrease of 220 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical device industry is 55.41, with a median of 37.94, placing Furuya Co., Ltd. at 107th in the industry ranking [2] - The company's static PE ratio is 101.48, and its price-to-book ratio is 6.45 [2]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Furuya Co., which has a current PE ratio of 110.92, marking a new low in 178 days, with a total market capitalization of 11.003 billion yuan [1][2] - Furuya Co. operates in the medical device industry, specifically focusing on liver disease-related pharmaceuticals, diagnostic equipment, and medical services, with its main product being the Compound Turtle Shell Soft Liver Tablets [1] - As of the first quarter of 2025, Furuya Co. reported a revenue of 330 million yuan, a year-on-year increase of 2.35%, and a net profit of 28.637 million yuan, reflecting a year-on-year decrease of 32.97%, with a gross profit margin of 76.76% [1] Group 2 - In comparison to the industry, Furuya Co.'s PE ratio is significantly higher than the industry average of 53.47 and the median of 37.00, ranking it 105th among its peers [1][2] - The company has 13 institutional investors holding a total of 6.5628 million shares, with a combined market value of 213 million yuan [1]